Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.

Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal. Fundam Clin Pharmacol. 2018 Oct;32(5):547 Authors: Hofer MD PMID: 30209857 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30209857?dopt=Abstract

Source: Clinical Prostate Cancer - September 15, 2018 Category: Cancer & Oncology Authors: Hofer MD Tags: Fundam Clin Pharmacol Source Type: research

More News: Cancer | Cancer & Oncology | Prostate Cancer